Objective:
To evaluate the efficacy and safety of vamikibart in treatment-naïve patients with diabetic macular edema (DME) compared to anti-VEGF therapy.
Key Findings:
- Vamikibart led to BCVA gains of approximately 6 letters from baseline across all doses.
- 15% to 23% of treatment-naïve patients gained 3 lines of vision (15 letters or more) with vamikibart.
- CST improved by 50 µm to 70 µm from baseline across dosing arms.
- 30% to 40% of patients had CST less than 325 µm post-treatment.
Interpretation:
Vamikibart monotherapy demonstrated significant improvements in both visual and anatomical outcomes in DME patients, indicating its potential as an effective treatment option.
Limitations:
- Higher incidence of ocular adverse events leading to treatment discontinuation in the vamikibart group.
- Increased intraocular inflammation observed with the higher dose of vamikibart.
Conclusion:
Vamikibart shows promise as a distinct therapeutic approach targeting IL-6 in DME, warranting further exploration of combination therapies with anti-VEGF.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.